Ieq Capital LLC Raises Position in Twist Bioscience Corporation $TWST

Key Points

• Ieq Capital LLC increased its position in Twist Bioscience by 40%, acquiring an additional 24,817 shares, bringing its total holdings to 86,851 shares valued at approximately $3.41 million.
• Several analysts have adjusted their price targets for Twist Bioscience, with Goldman Sachs lowering its target from $55 to $48, while other firms maintained or issued "buy" ratings, resulting in a consensus target price of $49.40.
• Insiders, including CEO Emily M. Leproust and CFO Adam Laponis, sold shares recently, indicating a decrease in their ownership by 0.26% and 2.31% respectively.

Ieq Capital LLC lifted its holdings in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 40.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 86,851 shares of the company's stock after buying an additional 24,817 shares during the period. Ieq Capital LLC owned approximately 0.14% of Twist Bioscience worth $3,410,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of TWST. Tower Research Capital LLC TRC lifted its stake in shares of Twist Bioscience by 30.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,059 shares of the company's stock worth $282,000 after buying an additional 1,414 shares in the last quarter. Stifel Financial Corp lifted its stake in shares of Twist Bioscience by 19.6% in the fourth quarter. Stifel Financial Corp now owns 8,331 shares of the company's stock worth $387,000 after buying an additional 1,364 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Twist Bioscience by 15.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 41,401 shares of the company's stock worth $1,924,000 after buying an additional 5,554 shares in the last quarter. Northern Trust Corp lifted its stake in shares of Twist Bioscience by 9.0% in the fourth quarter. Northern Trust Corp now owns 627,649 shares of the company's stock worth $29,167,000 after buying an additional 51,926 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of Twist Bioscience in the fourth quarter worth about $2,677,000.

Twist Bioscience Trading Up 0.2%

Shares of Twist Bioscience stock traded up $0.05 on Friday, reaching $25.68. The company had a trading volume of 340,979 shares, compared to its average volume of 1,188,383. The firm's 50 day moving average price is $31.94 and its two-hundred day moving average price is $35.02. The firm has a market cap of $1.55 billion, a PE ratio of -17.72 and a beta of 2.31. Twist Bioscience Corporation has a 52-week low of $24.28 and a 52-week high of $55.33. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.60 and a current ratio of 3.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.54) by $0.07. The business had revenue of $96.06 million for the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Sell-side analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Adam Laponis sold 2,449 shares of the business's stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $38.15, for a total value of $93,429.35. Following the sale, the chief financial officer directly owned 103,569 shares of the company's stock, valued at approximately $3,951,157.35. The trade was a 2.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Emily M. Leproust sold 1,678 shares of the business's stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $35.76, for a total transaction of $60,005.28. Following the completion of the sale, the chief executive officer directly owned 645,782 shares in the company, valued at $23,093,164.32. This trade represents a 0.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 5,250 shares of company stock worth $193,852 over the last three months. Insiders own 3.01% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Cowen reaffirmed a "buy" rating on shares of Twist Bioscience in a research note on Monday, August 4th. Evercore ISI set a $46.00 price target on shares of Twist Bioscience in a report on Monday, August 4th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Twist Bioscience has an average rating of "Moderate Buy" and an average price target of $49.40.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.